Literature DB >> 11464058

Male lower urinary tract symptoms and related health care seeking in Germany.

R R Berges1, L Pientka, K Höfner, T Senge, U Jonas.   

Abstract

OBJECTIVES: To investigate the prevalence of lower urinary tract symptoms (LUTS) and LUTS- related health care issues in the male population between the ages of 50 and 80 in Germany.
METHODS: 8,973 randomly chosen men in the age group of interest received by mail a self-administered questionnaire addressing voiding symptoms and bother, common health status, and social demographic as well as health care resources related issues.
RESULTS: Of 6,031 (67.2%) returned questionnaires, 5,404 (60.2%) were properly filled out and entered into the database. Of these, 5,004 (56%) completed all IPSS questions. 3,539 (70.7%) of the men presented with no or mild LUTS (IPSS 0--7), 1,465 (29,3%) with moderate to severe voiding symptoms (IPSS >7), respectively. From logistic regression analysis it appears that mainly bother from voiding symptoms as well as incomplete emptying and week stream induced a visit to the doctor. Of men with moderate symptoms (IPSS 8--19), 40% did not report any bother.
CONCLUSION: LUTS is a common condition among German elderly males. In general, bother from LUTS seem to have more effects on health care seeking behavior than symptoms themselves or physical health status. Bother scores may discriminate between those individuals with moderate symptoms (IPSS 8--19), who may be followed through watchful waiting instead of active therapy.

Entities:  

Mesh:

Year:  2001        PMID: 11464058     DOI: 10.1159/000052527

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  26 in total

1.  [Urological illnesses in the elderly].

Authors:  J M Wolff
Journal:  Urologe A       Date:  2004-08       Impact factor: 0.639

2.  [S2e guideline of the German urologists: Conservative and pharmacologic treatment of benign prostatic hyperplasia].

Authors:  K Höfner; T Bach; R Berges; K Dreikorn; C Gratzke; S Madersbacher; M-S Michel; R Muschter; M Oelke; O Reich; C Tschuschke; T Bschleipfer
Journal:  Urologe A       Date:  2016-02       Impact factor: 0.639

3.  Safety and efficacy of the potassium-titanyl-phosphate laser and photoselective vaporization of the prostate for benign prostatic hyperplasia.

Authors:  Claus G Roehrborn
Journal:  Rev Urol       Date:  2006

4.  [Benign prostate hyperplasia].

Authors:  U Jonas; A I Gabouev; T R W Herrmann; K Höfner; M C Michel; M Alschibaja; R Hartung
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

Review 5.  Short-, Intermediate-, and Long-term Quality of Life Outcomes Following Radical Prostatectomy for Clinically Localized Prostate Cancer.

Authors:  Vinay Prabhu; Ted Lee; Tyler R McClintock; Herbert Lepor
Journal:  Rev Urol       Date:  2013

6.  [Diagnostic and differential diagnosis of benign prostate syndrome (BPS): guidelines of the German Urologists].

Authors:  R Berges; K Dreikorn; K Höfner; S Madersbacher; M C Michel; R Muschter; M Oelke; O Reich; W Rulf; C Tschuschke; U Tunn
Journal:  Urologe A       Date:  2009-11       Impact factor: 0.639

Review 7.  [Anesthesia in endourological and robot-assisted interventions].

Authors:  T Kiss; T Bluth; A Heller
Journal:  Anaesthesist       Date:  2012-08       Impact factor: 1.041

Review 8.  [Primary and secondary prevention of benign prostatic hyperplasia: current knowledge and implications for clinical management].

Authors:  M Oelke; S Madersbacher
Journal:  Urologe A       Date:  2011-10       Impact factor: 0.639

9.  Latest developments in the assessment and treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: what is clinically relevant?

Authors:  Matthias Oelke
Journal:  Clin Drug Investig       Date:  2015-02       Impact factor: 2.859

10.  Quality of life in patients with overactive bladder: validation and psychometric properties of the Spanish Overactive Bladder Questionnaire-short Form.

Authors:  Salvador Arlandis; Miguel A Ruiz; Carlos Errando; Felipe Villacampa; Daniel Arumí; Isabel Lizarraga; Javier Rejas
Journal:  Clin Drug Investig       Date:  2012-08-01       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.